WO2003033494A1 - Benzimidazole derivative - Google Patents
Benzimidazole derivative Download PDFInfo
- Publication number
- WO2003033494A1 WO2003033494A1 PCT/JP2002/010706 JP0210706W WO03033494A1 WO 2003033494 A1 WO2003033494 A1 WO 2003033494A1 JP 0210706 W JP0210706 W JP 0210706W WO 03033494 A1 WO03033494 A1 WO 03033494A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- benzimidazole derivative
- alkyl
- represented
- useful
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A compound having excellent inhibitory activity against cancer cells and useful as an antitumor agent, which is represented by the following general formula (I): (I) (wherein R1 represents C3-6 branched alkyl and R2 represents hydrogen or C1-6 alkyl); or a pharmacologically acceptable salt of the compound.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001319632 | 2001-10-17 | ||
JP2001-319632 | 2001-10-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003033494A1 true WO2003033494A1 (en) | 2003-04-24 |
Family
ID=19137154
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2002/010706 WO2003033494A1 (en) | 2001-10-17 | 2002-10-16 | Benzimidazole derivative |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2003033494A1 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8969581B2 (en) | 2013-03-14 | 2015-03-03 | Deuterx, Llc | 5-deutero-2,4-thiazolidinedione derivatives and compositions comprising and methods of using the same |
US9925175B2 (en) | 2007-09-26 | 2018-03-27 | Deuterx, Llc | Deuterium-enriched pioglitazone |
US10188639B2 (en) | 2014-01-15 | 2019-01-29 | Deuterx, Llc | Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone |
US11319313B2 (en) | 2020-06-30 | 2022-05-03 | Poxel Sa | Crystalline forms of deuterium-enriched pioglitazone |
US11767317B1 (en) | 2020-06-30 | 2023-09-26 | Poxel Sa | Methods of synthesizing enantiopure deuterium-enriched pioglitazone |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999018081A1 (en) * | 1997-10-08 | 1999-04-15 | Sankyo Company, Limited | Substituted fused heterocyclic compounds |
WO2000061581A1 (en) * | 1999-04-07 | 2000-10-19 | Sankyo Company, Limited | Amine derivatives |
JP2000351769A (en) * | 1999-04-07 | 2000-12-19 | Sankyo Co Ltd | Insulin resistance improver |
WO2001083427A1 (en) * | 2000-04-28 | 2001-11-08 | Sankyo Company, Limited | PPARη MODULATORS |
WO2002013864A1 (en) * | 2000-08-16 | 2002-02-21 | Sankyo Company, Limited | Medicinal compositions for preventing and treating cancer |
JP2002179568A (en) * | 2000-10-06 | 2002-06-26 | Sankyo Co Ltd | Prophylactic agent or therapeutic agent comprising amine derivative compound |
-
2002
- 2002-10-16 WO PCT/JP2002/010706 patent/WO2003033494A1/en active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999018081A1 (en) * | 1997-10-08 | 1999-04-15 | Sankyo Company, Limited | Substituted fused heterocyclic compounds |
WO2000061581A1 (en) * | 1999-04-07 | 2000-10-19 | Sankyo Company, Limited | Amine derivatives |
JP2000351769A (en) * | 1999-04-07 | 2000-12-19 | Sankyo Co Ltd | Insulin resistance improver |
WO2001083427A1 (en) * | 2000-04-28 | 2001-11-08 | Sankyo Company, Limited | PPARη MODULATORS |
WO2002013864A1 (en) * | 2000-08-16 | 2002-02-21 | Sankyo Company, Limited | Medicinal compositions for preventing and treating cancer |
JP2002179568A (en) * | 2000-10-06 | 2002-06-26 | Sankyo Co Ltd | Prophylactic agent or therapeutic agent comprising amine derivative compound |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10576071B2 (en) | 2007-09-26 | 2020-03-03 | Poxel Sa | Deuterium-enriched pioglitazone |
US10940143B2 (en) | 2007-09-26 | 2021-03-09 | Poxel Sa | Deuterium-enriched pioglitazone |
US11918567B2 (en) | 2007-09-26 | 2024-03-05 | Poxel Sa | Deuterium-enriched pioglitazone |
US9925175B2 (en) | 2007-09-26 | 2018-03-27 | Deuterx, Llc | Deuterium-enriched pioglitazone |
US11123336B2 (en) | 2013-03-14 | 2021-09-21 | Poxel Sa | 5-deutero-2,4-thiazolidinedione derivatives and compositions comprising and methods of using the same |
US10265305B2 (en) | 2013-03-14 | 2019-04-23 | Poxel Sa | 5-deutero-2,4-thiazolidinedione derivatives and compositions comprising and methods of using the same |
US9416117B2 (en) | 2013-03-14 | 2016-08-16 | Deuterx, Llc | 5-deutero-2,4-thiazolidinedione derivatives and compositions comprising and methods of using the same |
US8969581B2 (en) | 2013-03-14 | 2015-03-03 | Deuterx, Llc | 5-deutero-2,4-thiazolidinedione derivatives and compositions comprising and methods of using the same |
US11918569B2 (en) | 2013-03-14 | 2024-03-05 | Poxel Sa | 5-deutero-2,4-thiazolidinedione derivatives and compositions comprising and methods of using the same |
US9833445B2 (en) | 2013-03-14 | 2017-12-05 | Deuterx, Llc | 5-deutero-2,4-thiazolidinedione derivatives and compositions comprising and methods of using the same |
US11141411B2 (en) | 2014-01-15 | 2021-10-12 | Poxel Sa | Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone |
US10188639B2 (en) | 2014-01-15 | 2019-01-29 | Deuterx, Llc | Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone |
US11319313B2 (en) | 2020-06-30 | 2022-05-03 | Poxel Sa | Crystalline forms of deuterium-enriched pioglitazone |
US11767317B1 (en) | 2020-06-30 | 2023-09-26 | Poxel Sa | Methods of synthesizing enantiopure deuterium-enriched pioglitazone |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2010003394A (en) | Bicyclic ?-amino acid derivative. | |
HK1069395A1 (en) | Phthalazinone derivatives 2,3 | |
MX2007004215A (en) | Process for the synthesis of 4-(3-methanesulfonylphenyl)-1-n- propyl-piperidine. | |
WO2009020140A1 (en) | Adamantylurea derivative | |
WO2005074603A3 (en) | Aminobenzoxazoles as therapeutic agents | |
CA2481591A1 (en) | Stabilized ascorbic acid derivatives | |
WO2001019828A3 (en) | Kinase inhibitors as therapeutic agents | |
EP1889842A4 (en) | Heterocyclic compound | |
NZ541974A (en) | Nucleotide phosphoramidates as anticancer agents | |
WO2005110410A3 (en) | Kinase inhibitors as therapeutic agents | |
TW200740805A (en) | Novel compounds | |
TW200612958A (en) | Substituted imidazole derivatives | |
WO2007014054A3 (en) | Benzenesulfonamide inhibitor of ccr2 chemokine receptor | |
MXPA02003977A (en) | INHIBITORS OF agr;L. | |
EP1568699A4 (en) | 1,3-dihydroimidazole fused-ring compound | |
TW200637539A (en) | CTGF inhibitors | |
WO2008078674A1 (en) | Glucokinase-activating substance | |
WO2009038064A1 (en) | Heterocyclic derivative having inhibitory activity on type-i 11β-hydroxysteroid dehydrogenase | |
WO2008105526A1 (en) | Macrocyclic compound | |
TW200637561A (en) | Antitumor agent | |
EP1634874A4 (en) | Imidazolidine derivative | |
AU7824900A (en) | Compounds and methods for inhibiting mrp1 | |
WO2005097100A3 (en) | Antibacterial agents | |
WO2004030664A3 (en) | New compounds for the inhibition of undesired cell proliferation and use thereof | |
EP1671957A4 (en) | Thiadiazoline derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |